Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Pharma Fujisawa Invests in Quark Biotech

NEW YORK, June 27 - Japanese pharmaceutical company Fujisawa has made an undisclosed equity investment in Quark Biotech (QBI), the companies said Wednesday. 

The investment is meant to accelerate the two companies' current collaboration, which dates to April 1999, Fujisawa said in a statement. At that time, Fujisawa agreed to pay research fees and milestone payments valued at $19 million for QBI, a genomics-based biopharmaceutical company based in Chicago, to discover genes related to stroke and develop drugs that target those genes. 

"The financial investment by Fujisawa is a tremendous affirmation of our mission to apply QBI's powerful genomic technology platform to the creation of promising new medicines for difficult-to-treat diseases, such as stroke," said Daniel Zurr, chief executive officer and founder of QBI, in a statement.

QBI also has research collaborations with other pharmaceutical companies, including Sankyo and Taisho Pharmaceutical, both based in Tokyo, to apply its gene expression and protein profiling technologies toward identifying drug targets and developing pharmaceuticals. QBI's research facilities are located in Israel and Chicago.  
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.